Andrew Polovin Biography and Net Worth

General Counsel of Tempus AI

Andy Polovin serves as General Counsel at Tempus, where he oversees and is responsible for various legal and business issues. Prior to joining Tempus, Andy was the General Counsel of Uptake Technologies, Inc., a company specializing in Artificial Intelligence software for heavy industry. Andy has also served as an Assistant United States Attorney focusing on narcotics and white-collar crime investigations; an equity partner at Bartlit Beck, one of the nation’s leading trial boutiques; and a Law Clerk to the Chief Judge of the U.S. Court of Appeals for the Seventh Circuit. Andy graduated from Colgate University and earned his law degree from Northwestern University School of Law.

What is Andrew Polovin's net worth?: The estimated net worth of Andrew Polovin is at least $8.21 million as of November 24th, 2025. Mr. Polovin owns 107,590 shares of Tempus AI stock worth more than $8,212,345 as of December 4th. This net worth evaluation does not reflect any other investments that Mr. Polovin may own. Learn More about Andrew Polovin's net worth.
How do I contact Andrew Polovin?: The corporate mailing address for Mr. Polovin and other Tempus AI executives is 600 WEST CHICAGO AVENUE SUITE 510, CHICAGO IL, 60654. Tempus AI can also be reached via phone at 800-976-5448 and via email at [email protected]. Learn More on Andrew Polovin's contact information.
Has Andrew Polovin been buying or selling shares of Tempus AI?: During the past quarter, Andrew Polovin has sold $1,741,384.92 of Tempus AI stock. Most recently, Andrew Polovin sold 12,874 shares of the business's stock in a transaction on Monday, November 24th. The shares were sold at an average price of $75.00, for a transaction totalling $965,550.00. Following the completion of the sale, the executive vice president now directly owns 107,590 shares of the company's stock, valued at $8,069,250. Learn More on Andrew Polovin's trading history.
Who are Tempus AI's active insiders?: Tempus AI's insider roster includes Ryan Bartolucci (CAO), Jennifer Doudna (Director), David Epstein (Director), Ryan Fukushima (COO), Eric Lefkofsky (Founder & CEO), Erik Phelps (EVP and Chief Administrative and Legal Officer), Andrew Polovin (General Counsel), James Rogers (CFO), and Nadja West (Director). Learn More on Tempus AI's active insiders.
Are insiders buying or selling shares of Tempus AI?: In the last year, insiders at the sold shares 81 times. They sold a total of 8,733,508 shares worth more than $520,802,581.27. The most recent insider tranaction occured on December, 1st when Director David R Epstein sold 250 shares worth more than $18,887.50. Insiders at Tempus AI own 26.3% of the company. Learn More about insider trades at Tempus AI.
Information on this page was last updated on 12/1/2025.

Andrew Polovin Insider Trading History at Tempus AI

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/24/2025	Sell	12,874	$75.00	$965,550.00	107,590
11/19/2025	Sell	6,387	$68.06	$434,699.22	120,464
11/18/2025	Sell	5,205	$65.54	$341,135.70	126,851
8/19/2025	Sell	5,398	$74.65	$402,960.70	132,056
5/20/2025	Sell	17,552	$63.43	$1,113,323.36	138,877
3/18/2025	Sell	13,135	$45.98	$603,947.30	154,171
12/16/2024	Sell	1,130	$40.23	$45,459.90	244,955
12/11/2024	Sell	51,504	$42.39	$2,183,254.56	246,085

Andrew Polovin Buying and Selling Activity at Tempus AI

Tempus AI Company Overview

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO.

Today's Range

Now: $76.33

$74.34

$78.09

50 Day Range

MA: $82.12

$65.69

$103.25

2 Week Range

Now: $76.33

$31.36

$104.32

Volume

3,635,907 shs

Average Volume

5,121,197 shs

Market Capitalization

$13.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.99